期刊文献+

CYP2C19基因多态性对奥美拉唑在中国人体内的药物动力学和药效学的影响 被引量:27

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese volunteers
下载PDF
导出
摘要 目的研究CYP2C19基因多态性对奥美拉唑在中国人体内的药物动力学和药效学的影响。方法在18例幽门螺杆菌感染阴性的健康志愿者中,应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)方法确定CYP2C19基因型,分为纯合子强代谢型(homEM),杂合子强代谢型(hetEM)和弱代谢型(PM)3组,每组6人。受试者口服奥美拉唑20 mg.d-1,连续8 d。分别在服药后d 1和d 8,应用高效液相色谱法测定奥美拉唑血药浓度,采用24 h胃内pH监测仪监测胃内pH情况。结果服用奥美拉唑d1,PM组的血药浓度-时间曲线下面积(AUC)高于homEM组和hetEM组,在三种基因型之间的相对比率为1∶1.1∶4.2(homEM∶hetEM∶PM);在服药d 8,PM组的AUC值也高于homEM组和hetEM组,在三种基因型之间的相对比率为1.0∶1.3∶3.3(homEM∶hetEM∶PM)。在服药d1,24 h胃内pH中位值、pH>3的总时间和pH>4的总时间在三种基因型间差异有显著性;在服药d 8,这些参数在PM组高于其它两组。结论CYP2C19基因多态性对奥美拉唑在中国人体内的药物动力学和药效学有明显影响。 Aim To investigate whether the pharmaco- dynamics and pharmacokinetics of omeprazole are dependent on the CYP2C19 genotype status in Chinese volunteers. Methods Eighteen healthy subjects voluntcered to participate in the study, whose CYP2C19 genotype status were determined with polymerase chain reaction-restriction fragment length polymorphism method. There were six homozygous extensive metabolizers, six heterozygous extensive metabolizers and six poor metabolizers. All subjects were H. pylori-negative, which were determined with serology and 13C-urea breath test. After d 1 and d 8 oral administration of omeprazole 20 mg once daily in the morning, intragastric pH values were monitored for 24 h with Digitrapper pH. Meanwhile, blood samples were collected at various time-points until 24 h after the administration. The serum concentrations of omeprazole were measured with high performance liquid chromatography. Results After a single dose, the PMs showed a significantly higher mean AUC value than that of the homEMs or hetEMs, with a relative ratio of 1.0 : 1.1 : 4.2(homEM : hetEM : PM);after repeated doses, the PMs also showed a significantly higher mean AUC value than that of the homEMs or hetEMs, with a relative ratio of 1.0 : 1.3 : 3.3(homEM : hetEM : PM). After a single dose of omeprazole, significant differences in intragastric pH median, pH 〉 3 holding time and pH 〉 4 holding time were observed among the three groups. After repeated doses, the PMs showed a significantly higher intragastric pH value than that of the homEMs or hetEMs. Conclusion The pharmacodynamic effects of omeprazole and its pharmacokinetics depend on the CYP2C19 genotype status in Chinese volunteers.
出处 《中国药理学通报》 CAS CSCD 北大核心 2005年第10期1210-1213,共4页 Chinese Pharmacological Bulletin
基金 安徽省教育厅基金资助项目(No2003kj199)
关键词 CYP2C19 基因多态性 奥美拉唑 药物动力学 药效学 CYP2C19 genetic polymorphism omeprazole pharmacokinetics pharmacodynamics
  • 相关文献

参考文献11

  • 1de Morais SM, Wilkinson GR, Blaisdell J et al. Identification of a new genetic defect responsible for the polymorphism of (S) -mephenytoin metabolism in Japanese[J]. Mol Pharmacol, 1994,46(4) :594 -8.
  • 2付良青,黄丰,吴德政,郭军华.中国健康志愿者的奥美拉唑及其代谢产物的药代动力学[J].中国药理学与毒理学杂志,2003,17(1):51-54. 被引量:21
  • 3Yamada S, Onda M, Kato S et al . Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations[J]. J Gastroenterol, 2001,36(10) :669 -72.
  • 4付良青,黄丰,吴德政,郭军华.反相高效液相色谱法测定奥美拉唑及其代谢产物5′-羟基奥美拉唑和奥美拉唑砜的血药浓度[J].中国药理学通报,2002,18(3):342-344. 被引量:5
  • 5Shirai N, Furuta T, Moriyama Yet al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH[J]. Aliment Pharmacol Ther 2001, 15(12) :1929 - 37.
  • 6Sakai T, Aoyama N, Kita T et al. CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects[J]. Pharm Res, 2001,18(6) :721 -7.
  • 7Andersson T, Cederberg C, Edvardsson G et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole[J]. Clin Pharmacol Ther, 1990,47(1) :79 -85.
  • 8Andersson T, Andren K, Cederberg C et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects[J]. Br J Clin Pharmacol, 1990,29(5) :557 -63.
  • 9Furuta T, Ohashl K, Kosuge K et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans[J]. Clin Pharmacol Ther, 1999, 65(5) : 552 -61.
  • 10Shimatani T, lnoue M, Kuroiwa T et al. Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist[J]. Aliment Pharmacol Ther, 2003,18 ( 11-12) :1149 -57.

二级参考文献14

  • 1[1]de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans[J]. J Biol Chem, 1994, 269(22):15419-15422.
  • 2[2]Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study[J]. Clin Pharmacol Ther, 1995, 57(6):662-669.
  • 3[3]Garcia-Encina G, Farran R, Puig S, Martinez L. Validation of an automated liquid chromatographic method for omeprazole in human plasma using on-line solid-phase extraction[J]. J Pharm Biomed Anal, 1999, 21(2):371-382.
  • 4[4]Fu LQ,Huang F, Wu DZ, Guo JH. The plasma concentration of omeprazole and metabolites 5′-hydroxyomeprazole, omeprazole sulphone are determinated by HPLC[J]. Chin Pharmacol Bull(中国药理学通报), 2002, 18(3):342-344.
  • 5[5]Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19[J]. Br J Clin Pharmacol, 1995, 39(5):511-518.
  • 6[6]Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and bioavai- lability of omeprazole after single and repeated oral administration in healthy subjects[J]. Br J Clin Pharmacol, 1990, 29(5):557-563.
  • 7[7]Andersson T, Regardh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators[J]. Ther Drug Monit, 1990, 12(4):415-416.
  • 8[8]Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SG, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population[J]. J Pharmacol Exp Ther, 1992, 262(3):1195-1202.
  • 9[9]Howden CW. Clinical pharmacology of omeprazole[J]. Clin Pharmacokinet, 1991, 20(1):38-49.
  • 10[10]Maton PN. Omeprazole[J]. N Engl J Med, 1991, 324(14):965-975.

共引文献24

同被引文献262

引证文献27

二级引证文献166

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部